Home » Stocks » IBIO

iBio, Inc. (IBIO)

Stock Price: $1.49 USD -0.02 (-1.32%)
Updated November 30, 4:00 PM EST - Market closed
Pre-market: $1.46 -0.03 (-2.01%) Dec 1, 4:06 AM

Stock Price Chart

Key Info

Market Cap 271.34M
Revenue (ttm) 1.94M
Net Income (ttm) -41.33M
Shares Out 182.11M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $1.49
Previous Close $1.51
Change ($) -0.02
Change (%) -1.32%
Day's Open 1.48
Day's Range 1.43 - 1.51
Day's Volume 7,019,700
52-Week Range 0.19 - 6.41

More Stats

Market Cap 271.34M
Enterprise Value 220.62M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 182.11M
Float n/a
EPS (basic) -0.67
EPS (diluted) -0.42
FCF / Share -0.12
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 12.71M
Short Ratio 2.11
Short % of Float n/a
Beta -5.94
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 139.87
PB Ratio 3.32
Revenue 1.94M
Operating Income -17.07M
Net Income -41.33M
Free Cash Flow -19.84M
Net Cash 50.72M
Net Cash / Share 0.28
Gross Margin 84.43%
Operating Margin -880.00%
Profit Margin -2,130.40%
FCF Margin -1,022.42%
ROA -14.00%
ROE -49.97%
ROIC -27.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$2.00*
Low
2.00
Current: $1.49
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue1.642.020.440.390.951.850.211.011.280.52
Revenue Growth-18.83%354.5%12.69%-58.44%-48.78%802.93%-79.64%-21.14%145.54%-
Gross Profit1.642.020.440.390.951.850.211.011.280.52
Operating Income-14.00-15.79-14.23-14.27-9.89-6.67-3.84-6.67-9.33-9.65
Net Income-16.44-17.59-16.11-14.53-9.76-6.63-3.67-6.20-5.68-12.14
Shares Outstanding62.8018.9310.638.918.107.156.304.943.953.10
Earnings Per Share-0.61-0.94-1.54-1.64-1.20-0.90-0.60-1.30-1.40-3.90
Operating Cash Flow-13.35-13.98-13.48-13.16-8.07-4.73-4.12-4.85-6.01-5.34
Capital Expenditures-1.15-0.99-1.08-1.59-0.07-0.22-0.26-0.20-0.25-0.09
Free Cash Flow-14.50-14.97-14.56-14.76-8.14-4.94-4.38-5.04-6.26-5.43
Cash & Equivalents55.114.4215.938.0923.019.493.594.415.622.84
Total Debt32.9124.8825.0825.2725.44-----
Net Cash / Debt22.20-20.46-9.15-17.18-2.429.493.594.415.622.84
Assets94.1930.5943.0836.0151.6012.496.499.359.777.34
Liabilities37.5828.1326.9227.1027.561.260.404.293.607.14
Book Value56.622.4616.178.919.9411.236.105.076.170.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name iBio, Inc.
Country United States
Employees 43
CEO Thomas F. Isett

Stock Information

Ticker Symbol IBIO
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: IBIO

Description

iBio, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.